Home > Company Introduction
Company Overview
Chengdu Seamaty Technology Co., Ltd has dedicated in the medical and veterinary diagnostic field since 2012, providing point of care testing (POCT) medical equipment worldwide. We have passed ISO 13485:2016 international quality management system certification. Our factory has equipped with 3 full-automatic production lines plus our professional quality control team to ensure high productivity and premium quality of products. Seamaty has subsidiaries in Shenzhen and Germany, while worked with dozens of partners around the world, and you could find our products and services in more than 80 countries and regions.
-
ManufacturerBusiness Type
-
2012Year Established
-
5,000-10,000 square metersFactory Size
-
US$10 Million - US$50 MillionAnnual Export Value
Company Detail
Transparency is the foundation of our partnership. Below is a comprehensive overview of our operational metrics, from business scale to global market reach, giving you a clear picture of our capabilities.
-
501 - 1000 People Total Employees
-
Above 100 People Sales Staff
-
Others Product Certifications
-
US$10 Million - US$50 Million Annual Export Value
-
North America, South America, Eastern Europe, Southeast Asia, Africa, Oceania, Mid East, Eastern Asia, Western Europe, Central America, Northern Europe, Southern Europe, South Asia, Domestic Market Main Markets
-
IVD Main Industry
-
Our ServicesSince 2012, we have been focusing on point-of-care testing (POCT) with years of industry experience. Engaged in medical and veterinary diagnosis, mainly providing instant diagnosis solutions for the medical and animal industry. We have six products, including biochemistry analyzer, immunoassay analyzer, hematology analyzer, blood gas & electrolytes analyzer, morphology analyzer and qPCR. -
Company History2012-2013: Seamaty was established; developed the first prototype and obtained two patents. 2014-2015: Received seed funding; established Polytech; passed ISO13485 certification. 2016-2017: Chemistry Analyzer obtained CE certification; recognized as National High-Tech Enterprise. 2018-2019: Expanded GMP production workshop; veterinary chemistry analyzer reached 40% domestic market share; obtained CFDA registration. 2020-2021: Established Shenzhen and German subsidiaries; developed blood gas & electrolyte analyzers; annual revenue exceeded USD 20 million. 2022-2023: Established six overseas subsidiaries; started Smart Factory construction. 2024-2025: Completed joint-stock reform; established Polish subsidiary; Smart Factory started production.
Our Certifications
Showcasing our professional qualifications and recognized industry certifications.